Meridian Bioscience

Meridian's diagnostics revenues grew 1 percent year over year to $36.4 million while its life science revenues jumped 8 percent to $15.4 million.

The firm saw modest growth in both its life science and diagnostics divisions and increased its guidance for the year.

The firm saw double-digit growth in both its core diagnostics and life sciences businesses, with losses in its Magellan lead testing division.

The firm saw a 6 percent increase in fiscal fourth quarter revenues, with growth in both its diagnostics and life science segments.

The firm attributes the positive results to efforts to strengthen its US diagnostics business and stabilize its core diagnostics product families of H. pylori and food testing.

The Index fell less than 1 percent in July, underperforming the Dow, the Nasdaq, and the Nasdaq Biotechnology Index.

The firm's life science segment grew revenues 8 percent, but revenues from its diagnostics segment saw revenues retreated 4 percent. 

The GenomeWeb Index rose nearly 3 percent in May, vastly outperforming the Dow and Nasdaq Biotechnology Index.

The company's second quarter revenue growth was driven in part by strong sales from its life science segment.

Pages

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.